tradingkey.logo

tradingkey.logo
怜玢


Sol Gel Technologies Ltd

SLGL
りォッチリストに远加
55.120USD
-1.130-2.01%
終倀 11-13 16:00ET
180.24M時䟡総額
損倱額盎近12ヶ月PER

Sol Gel Technologies Ltdに぀いお 䌁業名

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd プロフィヌル


䌁業コヌドSLGL
䌚瀟名Sol Gel Technologies Ltd
䞊堎日Feb 01, 2018
最高経営責任者「CEO」- -
埓業員数34
蚌刞皮類Ordinary Share
決算期末Feb 01
本瀟所圚地Golda Meir 7
郜垂NESS-ZIONA
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Israel
郵䟿番号- -
電話番号97289313433
りェブサむトhttp://www.sol-gel.com
䌁業コヌドSLGL
䞊堎日Feb 01, 2018
最高経営責任者「CEO」- -

Sol Gel Technologies Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
1.46K
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
1.00K
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
1.46K
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
1.00K
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--

よくある質問

Sol Gel Technologies Ltdの䞊䜍5名の株䞻は誰ですか


Sol Gel Technologies Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Moshe (Mori) Arkin

Sol Gel Technologies LtdSLGLの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Sol Gel Technologies Ltdの株匏を保有しおいる機関は39瀟あり、保有株匏の総垂堎䟡倀は玄1.00Mで、党䜓の30.93%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-175336.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。